AVAC Report 2018: No Prevention, No End!
October 18, 2018
AVAC's 2018 annual state of the field report, No Prevention, No End! looks at today's prevention crisis and offers context, analysis and strategy to turn that crisis around.
PrEP Watch is a clearinghouse for PrEP data, research, cost, access, implementation and advocacy efforts across the globe.
Where do you fit on the map?
Countries are at varying stages of introducing daily oral PrEP using TDF/FTC, which is now recommended by WHO as an option for people at substantial risk of HIV. Some countries have national programs; others have smaller-scale programs; others aren’t offering PrEP at all.
In this map, yellow countries have some form of PrEP programming; blue countries do not. Check back for regular updates!
A Framework for Scaling Up PrEP
This framework outlines the steps in this process for PrEP programs to have an impact and provides links to specific tools and resources for the following steps.
News Spotlight
-
-
CHARISMA Project Update: Photo story and HIV R4P satellite session
September 17, 2018
The CHARISMA intervention pilot—embedded in the MTN HOPE study—addressed intimate partner violence and relationship skills among women using microbicides in Johannesburg, South Africa. View the photo story to learn about the pilot through the eyes of CHARISMA clinic and community staff.
-
PrEP Spreads Across Africa – Slowly
August 6, 2018
Pilot PrEP projects have been underway in some African countries for several years. But it has only been since late 2017 that some countries have started serious PrEP availability programmes for wider populations.
-
On Demand PrEP Works as Well as Daily PrEP for Men Who Have Sex with Men
July 24, 2018
Not a single gay man who took two HIV prevention pills before and after sex had contracted HIV within a year thereafter, new research has found.
-
-
Rising Cost Of PrEP To Prevent HIV Infection Pushes It Out Of Reach For Many
June 30, 2018
Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections. But the officials are hitting roadblocks — the drug's price tag, which has surged in recent years, and changes in insurance coverage that put a heftier financial burden on patients.